Skip to main content

UBRS20139 / FACT-5 / Ajay Dhakal

Basic Study Information

The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on the CELsignia results.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Ajay Dhakal

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search